Hannah Clarke

The code, J9282, will be effective on January 1, 2026.

Take a look through the top readouts in urologic oncology from ESMO 2025.

Three cycles of chemotherapy was shown to improve patient-reported outcomes vs six cycles, with no detriment to overall survival.

Initial data on pasritamig showed that the agent was well tolerated and had encouraging preliminary antitumor activity in patients with mCRPC.

Data indicates that the DFS improvement was largely driven by the treatment effect in the higher risk population.

The PDUFA target action date for the application is April 7, 2026.

Data from the phase 3 ALBAN trial showed that atezolizumab plus BCG did not improve EFS compared with BCG alone.

The new CPT code will be effective starting on July 1, 2026.

The phase 2 Co-PSMA trial has met its primary end point.

The trial will assess the effect of adding docetaxel to SOC hormone therapy plus apalutamide in mCSPC.

The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.

SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.

The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

Data showed that adding niraparib to AAP significantly improved radiographic progression-free survival in this patient population.

Data from the ARC-20 trial show promising efficacy and a manageable safety profile for casdatifan monotherapy.

This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.

The addition of radiation after surgery improved clinical outcomes while not increasing severe late toxicity in this setting.

The review summarizes results from the OPTIMA II, ATLAS, and ENVISION trials.

Here’s a look back at notable news between July and September 2025.

Take a look back at the notable regulatory decisions in benign urology between July and September.

We recap notable headlines from last month in the urologic oncology space.

We recap notable headlines from last month in the benign urology space.

A recap of the FDA submissions and regulatory decisions in urology from September 2025.

The device features a 12 French working channel, the largest of any flexible single-use cystoscope.

Daniel Spratt, MD, presented data validating the PAM50 gene expression signature as the first predictive biomarker to guide hormone therapy in prostate cancer.

A comprehensive guide to the key regulatory decisions and conferences slated for the last few months of the year.

According to the authors, CAN-2409 may represent the first new treatment option for men with localized prostate cancer in over 2 decades.

The PREDICT-RT trial is evaluating intensified or de-intensified concurrent hormone therapy and radiation regimens in high-risk prostate cancer.